A compact diagnostic device developed in Melbourne could fundamentally change how Australians are tested for sexually transmitted infections, according to reporting by The Sydney Morning Herald. Roughly the size of a laptop, the machine is designed to detect STIs by scanning for distinct genetic "barcodes" unique to each pathogen, a method that promises both faster turnaround and sharper accuracy than conventional laboratory testing.
Under current standard practice, patients who present for STI screening typically wait several days for results after their sample is sent to a centralised pathology laboratory. That delay carries real consequences. People may not return for treatment, partners are not notified promptly, and infections continue to circulate. The new device is designed to close that gap by enabling results closer to the point of care, potentially within a single clinical visit.
The underlying principle relies on molecular identification: each pathogen carries a genetically distinct sequence, and the device reads these sequences as identifying markers, much like barcodes on a product. This approach is more precise than tests based solely on observed symptoms, which can result in overtreatment, or alternatively missed treatment, as many STIs produce no obvious clinical signs.
The clinical case for faster point-of-care testing in this space is well established. An Australian study in Melbourne found that the implementation of point-of-care testing was associated with reduced antibiotic prescription, more specific STI treatment among symptomatic clients, and an increase in rapid notification of sexual partners. Separate research found cost savings per client ranging from 13 to 35 per cent compared with standard care for both symptomatic and asymptomatic contacts.
Victoria's public health system has been actively investing in STI innovation. The Melbourne Sexual Health Centre has introduced innovations in STI testing and service delivery to respond to increasing STI rates and service demand. The state's broader ambitions are captured in the Victorian STI Plan 2022–30, which outlines priority actions to strengthen sexual health and reduce transmission through prevention, testing, and treatment.
Globally, the push toward rapid molecular diagnostics has accelerated considerably. UK-based Linear Diagnostics, for instance, has developed a rapid STI test built on ultra-fast DNA amplification technology capable of delivering lab-accurate results in as little as five minutes, without sending samples to centralised labs. The Melbourne device described by the SMH operates on similar logic, though with its own genetic barcode identification method, and is being positioned specifically for the Australian clinical context.
There are, of course, legitimate questions to answer before any new diagnostic tool earns a routine place in clinical practice. Regulatory approval from the Therapeutic Goods Administration is required before a medical device can be used on Australian patients. Beyond that, the question of Medicare reimbursement is critical: a device that delivers faster results but sits outside the rebate system will remain out of reach for many patients, particularly in lower socio-economic communities where STI rates tend to be higher.
Advocates for sexual health equity argue that any new testing technology must be assessed not just for clinical performance but for accessibility. Access to affordable testing in regional and rural areas remains a persistent challenge, something that Victoria's own vending-machine-based STI self-testing pilot, STI-X, was designed to address for patients too far from a clinic. A portable device capable of sitting in a GP's office or community health centre carries obvious appeal for those communities.
The honest assessment is that the science here looks promising and the public health rationale is clear. Faster, more accurate STI testing means earlier treatment, fewer missed diagnoses, and more effective partner notification. Whether this particular device can clear the regulatory, funding, and logistical hurdles required to reach everyday Australians is the harder and more important question. The answer will depend as much on health system decision-making as on the technology itself.